Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

Galunisertib (LY2157299) is a selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation currently under clinical investigation in hepatocellular carcinoma (HCC) patients. Our study explored the effects of galunisertib in vitro in HCC cell lines and ex vivo on patient samples. Galunisertib...

Descripción completa

Detalles Bibliográficos
Autores principales: Serova, Maria, Tijeras-Raballand, Annemilaï, Santos, Célia Dos, Albuquerque, Miguel, Paradis, Valerie, Neuzillet, Cindy, Benhadji, Karim A., Raymond, Eric, Faivre, Sandrine, de Gramont, Armand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673290/
https://www.ncbi.nlm.nih.gov/pubmed/26057634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673290/
https://www.ncbi.nlm.nih.gov/pubmed/26057634

Ejemplares similares